Median CD95 expression and proportion of CD8+cells within the CD57+ and CD57− compartments of individual TCRVβ subfamilies in 2 patients
| . | Vβ in CD3+ T cells, %* . | 3 SD above mean of age-matched controls . | CD8 in Vβ+cells, % . | CD95 expression in CD57+TCRVβ+ cells (MCF)† . | CD8 in CD57+ TCRVβ+ cells, %‡ . | CD95 expression in CD57−TCRVβ+ cells (MCF)2-153 . | CD8 in CD57− TCRVβ+ cells, %‡ . |
|---|---|---|---|---|---|---|---|
| Patient A | |||||||
| Vβ1 | 12.82-155 | 6.2 | 87.0 | 59 | 81.4 | 92 | 83.4 |
| Vβ2 | 5.0 | 14.5 | 69.0 | 54 | 84.9 | 174 | 32.3 |
| Vβ3 | 10.1 | 10.7 | 91.0 | 59 | 97.1 | 121 | 64.7 |
| Vβ7 | 1.7 | 4.7 | 69.0 | 80 | 72.7 | 161 | 43.1 |
| Vβ8 | 3.6 | 8.8 | 68.0 | 71 | 89.9 | 151 | 41.5 |
| Vβ13.6 | 2.5 | 4.5 | 81.0 | 75 | 99.6 | 178 | 21.3 |
| Vβ17 | 1.5 | 9.3 | 30.0 | 75 | 17.3 | 169 | 18.5 |
| Patient B | |||||||
| Vβ1 | 8.82-155 | 6.2 | 59.0 | 72 | 97.6 | 186 | 32.8 |
| Vβ2 | 13.0 | 14.5 | 22.0 | 78 | 18.8 | 170 | 16.1 |
| Vβ7 | 9.02-155 | 4.7 | 34.0 | 77 | 98.8 | 136 | 63.5 |
| Vβ8 | 7.5 | 8.8 | 23.0 | 70 | 62.0 | 199 | 16.6 |
| Vβ13.6 | 4.82-155 | 4.5 | 20.0 | 100 | 75.3 | 182 | 27.2 |
| Vβ16 | 1.8 | 2.5 | 23.0 | 87 | 16.7 | 178 | 18.9 |
| Vβ17 | 6.3 | 9.3 | 27.0 | 82 | 53.0 | 175 | 23.2 |
| . | Vβ in CD3+ T cells, %* . | 3 SD above mean of age-matched controls . | CD8 in Vβ+cells, % . | CD95 expression in CD57+TCRVβ+ cells (MCF)† . | CD8 in CD57+ TCRVβ+ cells, %‡ . | CD95 expression in CD57−TCRVβ+ cells (MCF)2-153 . | CD8 in CD57− TCRVβ+ cells, %‡ . |
|---|---|---|---|---|---|---|---|
| Patient A | |||||||
| Vβ1 | 12.82-155 | 6.2 | 87.0 | 59 | 81.4 | 92 | 83.4 |
| Vβ2 | 5.0 | 14.5 | 69.0 | 54 | 84.9 | 174 | 32.3 |
| Vβ3 | 10.1 | 10.7 | 91.0 | 59 | 97.1 | 121 | 64.7 |
| Vβ7 | 1.7 | 4.7 | 69.0 | 80 | 72.7 | 161 | 43.1 |
| Vβ8 | 3.6 | 8.8 | 68.0 | 71 | 89.9 | 151 | 41.5 |
| Vβ13.6 | 2.5 | 4.5 | 81.0 | 75 | 99.6 | 178 | 21.3 |
| Vβ17 | 1.5 | 9.3 | 30.0 | 75 | 17.3 | 169 | 18.5 |
| Patient B | |||||||
| Vβ1 | 8.82-155 | 6.2 | 59.0 | 72 | 97.6 | 186 | 32.8 |
| Vβ2 | 13.0 | 14.5 | 22.0 | 78 | 18.8 | 170 | 16.1 |
| Vβ7 | 9.02-155 | 4.7 | 34.0 | 77 | 98.8 | 136 | 63.5 |
| Vβ8 | 7.5 | 8.8 | 23.0 | 70 | 62.0 | 199 | 16.6 |
| Vβ13.6 | 4.82-155 | 4.5 | 20.0 | 100 | 75.3 | 182 | 27.2 |
| Vβ16 | 1.8 | 2.5 | 23.0 | 87 | 16.7 | 178 | 18.9 |
| Vβ17 | 6.3 | 9.3 | 27.0 | 82 | 53.0 | 175 | 23.2 |
CD95 expression results of the 2 multiple myeloma patients A and B have been graphed in Figure 5A.
MCF indicates median channel fluorescence.
The normal range of individual TCRVβsubfamilies was established by means of the age-matched controls.
For this column, the mean expression was 74; median, 75; and SD, 12.
The percentage of CD8+ cells in the CD57+ and CD57− subpopulations of each Vβ subset was calculated from the 3-color flow analysis for specific TCRVβ, CD8, and CD57.
For this column, the mean expression was 162; media, 172; and SD, 29.
Indicates expanded TCRVβ population.